


Clinical Management of Adrenocortical Carcinoma (ACC)

Presenter



Mouhammed Amir Habra, MD ASSOCIATE PROFESSOR

Dept. of Endocrine Neoplasia and Hormonal Disorders Associate Professor at MD Anderson Cancer MD Anderson Cancer Center Houston, TX

Disclosures

Exelixis: Research support

HRA Pharma Rare Diseases: Consultant

Corcept Therapeutics: Consultant

Calico: Consultant



- Review the epidemiology, clinical features, diagnosis, staging, and prognosis of adrenocortical carcinoma
- Summarize the management of advanced adrenocortical carcinoma
- Discuss the use of mitotane in ACC (dosing, adverse effects, and monitoring)



Introduction to ACC

Definition Epidemiology

Epidemiology of ACC

ACC: malignant tumor of the cortex

Adrenocortical carcinoma (ACC) is a malignant tumor of the adrenal cortex¹

ACC is an orphan disease

- Incidence: 1-2/million/year^{1,2}
- ACC affects more women than men (ratio: 1.5:1)²

It has a **bimodal distribution**¹


- Adults 40-55 years old^{3,4}
- Children younger than 10 years

Worldwide incidence in children: 0.2 to 0.3 per million per year (although may be higher in particular populations)³

ACC: adrenocortical carcinoma



Allolio B, Fassnacht M. J Clin Endocrinol Metab. 2006;91(6):2027-37.
 Fassnacht M, Allolio B. Best Pract Res Clin Endocrinol Metab. 2009;23(2):273-89
 Else T, et al. Endocr Rev. 2014;35(2):282-326.
 Jasim S, Habra MA. Curr Oncol Rep. 2019;21(3):20.



Age/Sex distribution at diagnosis of ACC²

Diagnosis Work-Up Imaging

Diagnostic work-up for ACC

Hormonal work up				
Glucocorticoid excess	 1-mg dexamethasone suppression test or free cortisol in 24-h urine¹ Basal ACTH (plasma)² 			
Sex steroids and steroid precursors ³	 DHEA-S 17-OH-progesterone Androstenedione Testosterone (only in women) 17-beta-estradiol (only in men and postmenopausal women) 11-deoxycortisol 			
Mineralocorticoid excess	 Potassium Aldosterone/renin ratio (only in patients with arterial hypertension and/or hypokalaemia) 			
Exclusion of a pheochromocytoma	Fractionated metanephrines in 24h urine or free plasma-metanephrines			
Imaging				
	 CT or MRI of abdomen and pelvis Chest CT FDG-PET/CT⁴ Bone or brain imaging (when skeletal or cerebral metastases are suspected) 			


The 1-mg dexamethasone test is the preferred method to exclude relevant hypercortisolism. However, if overt Cushing syndrome is evident, then cortisol in 24-h urine might be at least as good to quantify the cortisol excess. Alternatively, salivary or serum bedtime cortisol can be used.


- 2. ACTH can be skipped if hypercortisolism is excluded.
- 3. The most suitable set of precursors and sex hormones has not yet been established and local availability might be taken into account.
- 4. The panel did not agree on the systematic use of FDG-PET/CT.

ACC: adrenocortical carcinoma; ACTH: adrenocorticotropic hormone; CT: computerized tomography; DHEA-S: Dehydroepiandrosterone sulphate, FDG-PET: fluorodeoxyglucose positron emission tomography; MRI: magnetic resonance imaging.

HRA Pharma Rare Diseases Fassnacht M, et al. Eur J Endocrinol.2018;179(4):G1-G46.

Imaging Diagnosis







Computed tomography scan with axial view of left adrenocortical carcinoma²



1.Elsayes KM, Caoili EM. *Appl Radiol*. 2011;40(9):14-9. 2.Panchani R, *et al. Indian J Endocrinol Metab*. 2012;16(Suppl 2):S378-81. DEVOTED TO THE RARE

Staging classification Prognostic factors

Staging systems for ACC¹

Stage	ENSAT
Stage 1	T1, N0, M0
Stage 2	T2, N0, M0
Stage 3	T1–2, N1, M0 T3– 4, N0, M0
Stage 4	T1– 4, N0 –1, M1

ENSAT requires extensive imaging; systematic lymph node resection; a complete surgical and pathological reports ²

T1: ≤5-cm tumour; T2: >5-cm tumour; T3: tumour infiltration into surrounding tissue; T4: tumour invasion into adjacent organs; N0: no positive lymph nodes; N1: positive lymph node(s); M0: no distant metastases; M1: presence of distant metastasis²



Prognosis

Prognosis of ACC is generally poor and depends on the stage¹


 Diagnosed at advanced stages in older series, but in the recent ones, highest percentage of patients were diagnosed in stage II through <u>available imaging technology</u>

Prognosis depends on stage³

- ACC has a poor prognosis
- Overall survival at 5 years is 13%-82%

Stage	5-year stage-dependent survival
-T	82%
П	61%
Ш	50%
IV	13%





ACC: adrenocortical carcinoma




Fassnacht M. Allolio B J Clin Endocrinol Metab. 2006;91(6):2027-37.
 Fassnacht M. Aliolio B Best Practice & Research Clinical Endocrinology & Metabolism 23 (2009) 273-289
 Fassnacht M, et al. Cancer. 2009;115(2):243-50.


DEVOTED TO THE RARE

Hormonal Overproduction in ACC

DEVOTED TO THE RARE




HRA Pharma Rare Diseases




Adapted from Abiven et al.





12

Prognostic Factors: Hormonal Activity



RR of cortisol production for Recurrence Free Survival

First				Relative	%
author	publication	Ν		risk (95% CI)	Weight
Adjusted es	timates (corre	ction for tumor stage)			
Berruti	2013	524		1.30 (1.04, 1.62)	54.34
Else	2014	391		1.49 (1.11, 2.00)	35.09
Margonis	2016	234		2.05 (1.16, 3.62)	10.57
Subtotal (I-squared = 13.6%, p = 0.314)			\diamond	1.43 (1.18, 1.73)	100.00
Unadjusted	estimates				
Berruti	2013	524	+	1.04 (0.97, 1.12)	35.05
Fassnacht	2012	304	÷.	1.04 (0.98, 1.11)	35.45
Else	2014	391		1.75 (1.33, 2.30)	19.89
Margonis	2016	234		- 2.59 (1.57, 4.27)	9.61
Subtotal (I-squared = 88.2%, p = 0.000)			\diamond	1.26 (1.05, 1.51)	100.00

Berruti et al. European Urology, 2014

Ayala-Ramirez et al. EJE, 2013




Ki-67 immunohistochemistry has been proposed for prognosis purpose¹

- The Ki-67 protein is highly expressed in cycling cells¹
- It has thus been reliably used as a proliferation marker for grading multiple cancers and differentiating benign from malignant cancer²



Prognostic Factors: Proliferation Rate (Ki67%)




Major Prognostic Role of Ki67 in Localized Adrenocortical Carcinoma After Complete Resection

Beuschlein et al. J Clin Endocrinol Metabol, 2015

HRAPharma

Prognostic Factors: Resection Margin



Effect of resection Margin on local recurrence (R0: negative margin) vs. (R1: microscopically positive)



ACC Management

European Society of Endocrinology Clinical Practice Guidelines on the Management of Adrenocortical Carcinoma in Adults, in collaboration with the European Network for the Study of Adrenal Tumors.

Fassnacht M, et al. Eur J Endocrinol. 2018;179(4):G1-G46.


Recommended treatments for Localized ACC

- Preoperative Management
- Surgical Management
- Surveillance



Fassnacht et al. Eur J Endocrinol, 2018

Recommendations advanced ACC not amenable to Resection



- 1. Only in selected patients (with severe hormone excess)
- The following factors might guide the decision: site of disease involvement, tumor burden, symptoms, tumor grade/Ki67 index
- 3. The following factors might guide the decision: site of disease involvement, tumor burden, symptoms, tumor grade/Ki67 index, and importantly kinetics of tumor growth
- 4. Radiotherapy, radiofrequency ablation, cryo-ablation, microwave ablation, (chemo-) embolization
- 5. Few panellists favored cisplatin + etoposide
- 6. Contact specialized center


ACC: adrenocortical carcinoma: EDP: etoposide, doxorubicin, cisplatin



Adapted from Fassnacht M, et al. Eur J Endocrinol. 2018; 179(4):G1-G46.

Systemic Chemotherapy: FIRM-ACT Trial EDP-Mitotane vs. Sz-Mitotane

- Response Rate 23% vs. 9%
- Median PFS 5 vs. 2.1 months
- Overall Survival 14.8 vs. 12 months







Only FDA approved treatment for inoperable, functional or nonfunctional, adrenal cortical carcinoma (ACC)

WARNINGS: ADRENAL CRISIS IN THE SETTING OF SHOCK OR SEVERE TRAUMA: In patients taking LYSODREN, adrenal crisis occurs in the setting of shock or severe trauma and response to shock is impaired. Administer hydrocortisone, monitor for escalating signs of shock and discontinue LYSODREN until recovery.



Lysodren[®] U.S. Package Insert

Mitotane Mechanism of Action

Mitotane is an Adrenal Cytotoxic Agent and Steroidogenesis Inhibitor

The mode of action is not fully understood¹

Data available suggest that mitotane:

- Modifies the peripheral metabolism of steroids and inhibits key enzymatic steps in cortisol synthesis²
- Directly suppresses the adrenal cortex²

Administration of mitotane alters the extra-adrenal metabolism in man, leading to:

- A reduction in measurable 17-hydroxy corticosteroids³
- Increase of 6-β-hydroxycortisol (inactive metabolite)³



Improvements in the Understanding of Mitotane's MOA

Original Research

- Mitotane alters mitochondrial respiratory chain activity by including cytochrome c oxidase defect in human adrenocortical cells¹
- Morphofunctional effects of mitotane on mitochondria in human adrenocortical cancer cells²
- Mitotane inhibits Sterol-O-Acyl Transferase 1 triggering lipid-mediated endoplasmic reticulum stress and apoptosis in ACC cells³

In adrenocortical cells, SOAT1 is a key target for mitotane³

- Alteration in lipid homeostasis \rightarrow ER stress \rightarrow apoptosis
- Steroidogenesis blockade



Mitotane alters complex IV of mitochondrial respiratory chain, leading to morphofunctional alterations^{1,2}

RARE

Mitotane Dosing and Plasma Monitoring

- Lipophilic and is stored in adipose tissues, fat is the primary site of distribution¹
- Prolonged half-life: median 53 days, range (18 159 days)¹
 - This delays the impact on mitotane plasma levels after dose changes and after treatment discontinuation
- Long onset of action (3-5 months)²
- Fat tissue can act as a reservoir for mitotane, resulting in a prolonged half-life and potential accumulation of mitotane. Despite a constant dose, mitotane levels may increase. Monitoring of mitotane plasma levels (e.g. every two months) is recommended after interruption of treatment, as prolonged release of mitotane can occur.²
- Caution and close monitoring of mitotane plasma levels are highly recommended when treating overweight patients²



Mitotane Dosage & Administration

• Initial dose: 2 to 6 grams orally daily, in 3 or 4 divided doses¹

2-6 g/day / 3-5 months¹

Clinical Effectiveness Assessment


Increase dose incrementally to achieve a blood concentration of **14 to 20 mg/L** or as tolerated. It can take 3 to 5 months¹.

Imaging assessment with thorax, abdomen and pelvis CT every 3 months for 2 years².

Optimal Blood Concentration



Mitotane Plasma Level Monitoring is to be performed on a regular and individual basis to reach/maintain an optimal therapeutic window²





1.Lysodren[®] U.S. Package Insert 2.Fassnacht M, Allolio B. *Best Pract Res Clin Endocrinol Metab.* 2009;23(2):273-89. DEVOTED TO THE RARE

Mitotane Warnings Precautions

Indicated for the treatment of inoperable ACC of both functional & non-functional types

WARNINGS: ADRENAL CRISIS IN THE SETTING OF SHOCK OR SEVERE TRAUMA: In patients taking LYSODREN, adrenal crisis occurs in the setting of shock or severe trauma and response to shock is impaired. Administer hydrocortisone, monitor for escalating signs of shock and discontinue LYSODREN until recovery.

- CNS Toxicity
- Adrenal Insufficiency
- Embryo-Fetal Toxicity
- Ovarian Macrocysts in Premenopausal Women

For more information please refer to the full U.S. Prescribing Information



Adrenal Insufficiency

- Mitotane is an adrenal cytolytic drug¹
- Generally spares the zona glomerulosa with selective loss of ACTH dependent adrenal zones (fasciculata and reticularis)¹
- In addition the drug inhibits key steroidogenic enzymes, most notably CYP11A1, decreasing conversion of cholesterol to pregnenolone²
- Consider beginning hydrocortisone replacement at the outset of mitotane therapy. Mitotane is strong inducer of Cytochrome P4503A4 (CYP3A4)³
- Causes rapid inactivation of >50% administered hydrocortisone³
- Usually requires at least double usual maintenance dose (i.e. 40-50 mg hydrocortisone a day in divided doses)³



Mitotane Drug Interactions

• Warfarin:

Mitotane has been reported to accelerate the metabolism of warfarin¹

• CYP 3A4 Substrates:

Mitotane is a strong inducer of cytochrome P450 3A4¹

Concomitant use of LYSODREN may decrease the concentrations of CYP3A substrates, which may
reduce the efficacy of these substrates. Avoid the concomitant use of LYSODREN with certain CYP3A4
substrates where minimal concentration changes may lead to therapeutic failure. If concomitant use
cannot be avoided, increase the CYP3A substrate dosage in accordance with approved product labeling.

• Hormone Binding Protein:

Mitotane has been shown to increase plasma levels of sex hormone binding proteins²



Adverse Events and Monitoring Plan

Mitotane Adverse Events

Most Common Adverse Effects

- Anorexia, nausea, vomiting, and diarrhea (80%)
- Depression, dizziness, or vertigo (15%-40%)
- Rash (15%)
- Neutropenia
- Hepatitis, elevation of liver enzymes

- Growth retardation, hypothyroidism
- Confusion, headache, ataxia, mental impairment, weakness, dysarthria
- Maculopathy
- Hypercholesterolemia, hypertriglyceridemia

- Decreased blood androstenedione and decreased blood testosterone in females, increased sex hormone binding globulin in females and males, decreased blood free testosterone in males
- Gynecomastia

Less Common Adverse Effects

- Hypertension
- Orthostatic hypotension, flushing
- Generalized aching, and fever
- Visual blurring

- Diplopia
- Lens opacity, retinopathy
- Prolonged bleeding time
- Hematuria

- Hemorrhagic cystitis
- Albuminuria
- Hypogonadism



Suggested Monitoring Plan

Test	Indication	Interval
CBC	Hematological toxicity	Q 3 months
Electrolytes	Monitor steroid replacement	Q 1-3 months
ACTH, Plasma Renin Activity	Monitor steroid replacement	Q 1-3 months
LFTs	Hepatic toxicity	Q 3 months
TSH, Free T4	Hypothyroidism	Q 3 months
Lipid panel	Hyperlipidemia	Q 3 months
Testosterone	Hypogonadism	If clinically indicated
Mitotane level	Titrate dose	 Q month till reaching level then q 2-3 months PRN if suspected toxicity





- A multidisciplinary team is needed to manage the complex medical issues seen in advanced ACC
- While there are no prospective data regarding hormonal management in ACC, therapy is suggested based on ESE/ENSAT 2018 guidelines
- Mitotane use should be supervised closely to achieve desired plasma level 14-20 mg/L and monitor adverse events
- Adrenal insufficiency is among the most common side effects during mitotane therapy and often requires higher than the average steroid replacement





Clinical Management of ACC

THANK YOU!

INDICATION

LYSODREN[®] is an adrenal cytotoxic agent indicated for the treatment of inoperable, functional or nonfunctional, adrenal cortical carcinoma.

IMPORTANT SAFETY INFORMATION

Warning/Adrenal crisis in the setting of shock or severe trauma: In patients taking LYSODREN[®], adrenal crisis occurs in the setting of shock or severe trauma and response to shock is impaired. Administer hydrocortisone, monitor for escalating signs of shock and discontinue LYSODREN[®] until recovery.

CNS Toxicity: CNS toxicity, including sedation, lethargy, and vertigo, occurs with LYSODREN[®] treatment. Mitotane plasma concentrations exceeding 20 mcg/mL are associated with a greater incidence of toxicity.

Adrenal Insufficiency: Treatment with LYSODREN[®] can cause adrenal insufficiency. Institute steroid replacement as clinically indicated. Measure free cortisol and corticotropin (ACTH) levels to achieve optimal steroid replacement.

Embryo-Fetal Toxicity: LYSODREN[®] can cause fetal harm when administered to a pregnant woman. Abnormal pregnancy outcomes, such as preterm births and early pregnancy loss, can occur in patients exposed to mitotane during pregnancy. Advise females of reproductive potential to use effective contraception during treatment with LYSODREN[®] and after discontinuation of treatment for as long as mitotane plasma levels are detectable.

Ovarian Macrocysts in Premenopausal Women: Ovarian macrocysts, often bilateral and multiple, have been reported in premenopausal patients receiving LYSODREN[®]. Complications from these cysts, including adnexal torsion and hemorrhagic cyst rupture, have been reported. In some cases, improvement after mitotane discontinuation has been described.

Ovarian Macrocysts in Premenopausal Women: Ovarian macrocysts, often bilateral and multiple, have been reported in premenopausal patients receiving LYSODREN[®]. Complications from these cysts, including adnexal torsion and hemorrhagic cyst rupture, have been reported. In some cases, improvement after mitotane discontinuation has been described.

Lactation: Mitotane is excreted in human milk; however, the effect of LYSODREN[®] on the breastfed infant, or effect on milk production is unknown. Because of the potential for serious adverse reactions in the breastfed infant, advise nursing women that breastfeeding is not recommended during treatment with LYSODREN[®] and after discontinuation of treatment for as long as mitotane plasma levels are detectable.

Hepatic Impairment: Administer LYSODREN[®] with caution to patients with hepatic impairment.

Common adverse reactions (≥15%) include: anorexia, nausea, vomiting and diarrhea; depression, dizziness or vertigo; and rash.

LYSODREN[®] is a cytotoxic drug. Follow applicable special handling and disposal procedures.

Please see **Full Prescribing Information**, including BOXED WARNING, for LYSODREN (mitotane) tablets.

To report SUSPECTED ADVERSE REACTIONS, contact Direct Success Pharmacy, Inc. at 1-844-LYSODREN (1-844-597-6373) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.